Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020934 | 0.87 | ALDH1A1 (0.40) | ALDH1A1GAALMNAHTTFFAR1 | |
| SCHEMBL15042181 | 0.86 | ALDH1A1 (0.40) | ALDH1A1GAAL3MBTL1LMNAHTT | |
| SCHEMBL10848249 | 0.84 | TSHR (0.49) | ALDH1A1GAAL3MBTL1LMNAHTT | |
| SCHEMBL11813324 | 0.82 | ALDH1A1 (0.49) | ALDH1A1GAALMNAHTTPOLB | |
| SCHEMBL3591959 | 0.81 | NPC1 (0.53) | ALDH1A1FFAR1ALOX5 | |
| SCHEMBL1055546 | 0.81 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1LMNAHTTPOLB | |
| SCHEMBL1095499 | 0.80 | ALDH1A1 (0.47) | ALDH1A1GAALMNAHTTFFAR1 | |
| SCHEMBL9149235 | 0.80 | CNR2 (0.57) | ALDH1A1L3MBTL1PBRM1ALOX5 | |
| SCHEMBL31724116 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GAANPSR1KMT2AALOX5 | |
| SCHEMBL27914975 | 0.79 | ALDH1A1 (0.46) | ALDH1A1GAAL3MBTL1FFAR1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| WO-2012030170-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | (주)아모레퍼시픽 (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | ALDH1A1 2139/4885GAA 3078/4885L3MBTL1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.